Literature DB >> 7014234

Granulocyte function in human allogenic marrow graft recipients.

R Sosa, P L Weiden, R Storb, J Syrotuck, E D Thomas.   

Abstract

Granulocyte chemotaxis and iodination were studied in 87 allogeneic marrow transplant recipients and in 25 normal individuals. Chemotactic responses of marrow transplant recipients as a group were depressed during the first 4 months after transplantation and normal in patients studied as long-term survivors (days 175--2202 post-transplantation). Patients with moderate to severe acute or chronic graft-versus-host disease (GVHD) or infections had lower chemotactic responses than those without. Granulocyte iodination and the ability of patient serum to support iodination were normal. Thus, depressed granulocyte chemotaxis recovered slowly with time following allogeneic marrow transplantation. Both acute and chronic GVHD, however, were associated with impairment of granulocyte chemotaxis, a defect which may contribute to the high risk of infection among allogeneic marrow graft recipients with GVHD.

Entities:  

Mesh:

Year:  1980        PMID: 7014234

Source DB:  PubMed          Journal:  Exp Hematol        ISSN: 0301-472X            Impact factor:   3.084


  3 in total

Review 1.  Immune reconstitution following bone marrow transplantation.

Authors:  U N Verma; A Mazumder
Journal:  Cancer Immunol Immunother       Date:  1993-11       Impact factor: 6.968

2.  Etiology, clinical features and outcomes of pre-engraftment and post-engraftment bloodstream infection in hematopoietic SCT recipients.

Authors:  C Gudiol; C Garcia-Vidal; M Arnan; I Sánchez-Ortega; B Patiño; R Duarte; J Carratalà
Journal:  Bone Marrow Transplant       Date:  2014-03-24       Impact factor: 5.483

3.  Assessment of Neutrophil Chemotaxis Upon G-CSF Treatment of Healthy Stem Cell Donors and in Allogeneic Transplant Recipients.

Authors:  Anna Thunström Salzer; Maria J Niemiec; Ava Hosseinzadeh; Marios Stylianou; Fredrik Åström; Marc Röhm; Clas Ahlm; Anders Wahlin; David Ermert; Constantin F Urban
Journal:  Front Immunol       Date:  2018-09-11       Impact factor: 7.561

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.